Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response

from Cancer via ola Kala on Inoreader http://ift.tt/2jOkLm5
via IFTTT